Production of recombinant DNA-binding protein HMGB1 for diagnostic application
Project goals
This project is focused on the development of immunoanalytical kit for HMGB1 protein quantification in biological samples. The final usage of the kit is in the field of research and development as well as in diagnostics. The main scope is the development of the technology of preparation of the main components, i.e. recombinant HMGB1 and monoclonal antibodies against HMGB1. Recombinant HMGB1 will be produced using various expression systems so that comparable biological activity with the native proteinwill be reached. Next to the utilization of recombinant HMGB1 for immunization and as a protein standard in diagnostics it will be tested for its potential therapeutic activity.
Keywords
recombinant proteinmonoclonal antibodyELISAimmunodiagnosticsHMGB1DNA vaccination
Public support
Provider
Ministry of Industry and Trade
Programme
TIP
Call for proposals
TIP 4 (SMPO2012/01)
Main participants
GENERI BIOTECH s.r.o.
Contest type
VS - Public tender
Contract ID
FR-TI4/504
Alternative language
Project name in Czech
Produkce rekombinantního DNA-vazebného proteinu HMGB1 pro diagnostické využití
Annotation in Czech
Tento projekt je zaměřen na vývoj imunoanalytické soupravy pro kvantifikaci HMGB1 ve vzorcích biologického původu s využitím ve výzkumu a vývoji a v diagnostice. Hlavní náplní je vývoj technologie přípravy vstupních komponent, tedy rekombinantního HMGB1a monoklonálních protilátek. Rekombinantní HMGB1 bude produkován s využitím různých produkčních systémů, tak aby bylo dosaženo biologické aktivity srovnatelné s nativním proteinem. Vedle využití HMGB1 v imunizacích a jako proteinového standardu v diagnostice, bude testován jeho potenciální terapeutický význam.
Scientific branches
R&D category
AP - Applied research
CEP classification - main branch
EI - Biotechnology and bionics
CEP - secondary branch
EB - Genetics and molecular biology
CEP - another secondary branch
—
10603 - Genetics and heredity (medical genetics to be 3)
10604 - Reproductive biology (medical aspects to be 3)
10605 - Developmental biology
10608 - Biochemistry and molecular biology
10609 - Biochemical research methods
20801 - Environmental biotechnology
20802 - Bioremediation, diagnostic biotechnologies (DNA chips and biosensing devices) in environmental management
20803 - Environmental biotechnology related ethics
20901 - Industrial biotechnology
20902 - Bioprocessing technologies (industrial processes relying on biological agents to drive the process) biocatalysis, fermentation
20903 - Bioproducts (products that are manufactured using biological material as feedstock) biomaterials, bioplastics, biofuels, bioderived bulk and fine chemicals, bio-derived novel materials
30101 - Human genetics
30401 - Health-related biotechnology
30402 - Technologies involving the manipulation of cells, tissues, organs or the whole organism (assisted reproduction)
30403 - Technologies involving identifying the functioning of DNA, proteins and enzymes and how they influence the onset of disease and maintenance of well-being (gene-based diagnostics and therapeutic interventions [pharmacogenomics, gene-based therapeutics])
30404 - Biomaterials (as related to medical implants, devices, sensors)
30405 - Medical biotechnology related ethics
40401 - Agricultural biotechnology and food biotechnology
40402 - GM technology (crops and livestock), livestock cloning, marker assisted selection, diagnostics (DNA chips and biosensing devices for the early/accurate detection of diseases) biomass feedstock production technologies, biopharming
40403 - Agricultural biotechnology related ethics
Completed project evaluation
Provider evaluation
U - Uspěl podle zadání (s publikovanými či patentovanými výsledky atd.)
Project results evaluation
The aim of the project was technology for production of HMGB1 protein, antibodies against this protein and connection of the results into ELISA kit. Despite some difficulties targets were fulfilled. The final product, imunoanalytical kit.
Solution timeline
Realization period - beginning
Jan 1, 2012
Realization period - end
Dec 31, 2015
Project status
U - Finished project
Latest support payment
Apr 25, 2014
Data delivery to CEP
Confidentiality
C - Předmět řešení projektu podléhá obchodnímu tajemství (§ 504 Občanského zákoníku), ale název projektu, cíle projektu a u ukončeného nebo zastaveného projektu zhodnocení výsledku řešení projektu (údaje P03, P04, P15, P19, P29, PN8) dodané do CEP, jsou upraveny tak, aby byly zveřejnitelné.
Data delivery code
CEP16-MPO-FR-U/03:1
Data delivery date
Feb 13, 2018
Finance
Total approved costs
17,650 thou. CZK
Public financial support
13,824 thou. CZK
Other public sources
0 thou. CZK
Non public and foreign sources
3,825 thou. CZK
Basic information
Recognised costs
17 650 CZK thou.
Public support
13 824 CZK thou.
78%
Provider
Ministry of Industry and Trade
CEP
EI - Biotechnology and bionics
Solution period
01. 01. 2012 - 31. 12. 2015